[go: up one dir, main page]

WO2012009382A3 - Molecular indicators of bladder cancer prognosis and prediction of treatment response - Google Patents

Molecular indicators of bladder cancer prognosis and prediction of treatment response Download PDF

Info

Publication number
WO2012009382A3
WO2012009382A3 PCT/US2011/043762 US2011043762W WO2012009382A3 WO 2012009382 A3 WO2012009382 A3 WO 2012009382A3 US 2011043762 W US2011043762 W US 2011043762W WO 2012009382 A3 WO2012009382 A3 WO 2012009382A3
Authority
WO
WIPO (PCT)
Prior art keywords
bladder cancer
prediction
treatment response
cancer prognosis
benefit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/043762
Other languages
French (fr)
Other versions
WO2012009382A2 (en
Inventor
Alex Baras
Jae K. Lee
Steven Smith
Dan Theodorescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Publication of WO2012009382A2 publication Critical patent/WO2012009382A2/en
Publication of WO2012009382A3 publication Critical patent/WO2012009382A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed are biomarkers, methods and assay systems for the identification of bladder cancer patients who are predicted to benefit, or not benefit from the therapeutic administration of neoadjuvant therapy. Particularly, the invention provides a diagnostic paradigm based on each of these tests and combinations of these tests to select bladder cancer patients who will or will not benefit from neoadjuvant chemotherapy, as well as a diagnostic paradigm to identify bladder cancer patients likely to suffer recurrence of cancer following cystectomy.
PCT/US2011/043762 2010-07-12 2011-07-12 Molecular indicators of bladder cancer prognosis and prediction of treatment response Ceased WO2012009382A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36333810P 2010-07-12 2010-07-12
US61/363,338 2010-07-12

Publications (2)

Publication Number Publication Date
WO2012009382A2 WO2012009382A2 (en) 2012-01-19
WO2012009382A3 true WO2012009382A3 (en) 2012-04-19

Family

ID=45470039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043762 Ceased WO2012009382A2 (en) 2010-07-12 2011-07-12 Molecular indicators of bladder cancer prognosis and prediction of treatment response

Country Status (1)

Country Link
WO (1) WO2012009382A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11101038B2 (en) 2015-01-20 2021-08-24 Nantomics, Llc Systems and methods for response prediction to chemotherapy in high grade bladder cancer

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135655A1 (en) * 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
EP3066217A4 (en) * 2013-11-04 2017-10-11 The University Of British Columbia Cancer biomarkers and classifiers and uses thereof
TW201725526A (en) 2015-09-30 2017-07-16 伊佛曼基因體有限公司 Systems and methods for predicting treatment-regimen-related outcomes
KR20200079524A (en) * 2017-10-30 2020-07-03 난토믹스, 엘엘씨 TEMOZOLOMIDE RESPONSE PREDICTOR AND METHODS
CN110806486B (en) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Application of MAFG/AS1/PCBP2/FPN1 regulation and control axis AS target site detection reagent
EP3868884A1 (en) * 2020-02-19 2021-08-25 Aarhus Universitet Method for subtyping bladder cancer using aptamers
CN115267187B (en) * 2022-05-10 2023-07-14 吉林大学 MCT1 positioning detection method and application thereof in urinary tract system cancer
CN115058504B (en) * 2022-07-14 2025-07-04 广州医科大学 Bladder cancer TH17 CD4+T cell subsets and their characteristic genes and applications
CN116381234B (en) * 2022-11-06 2025-07-15 复旦大学 Application of MMP14 as a molecular marker and therapeutic target for leptomeningeal metastases
CN119001103A (en) * 2024-08-09 2024-11-22 中南大学湘雅医院 Biomarker for evaluating prognosis survival of bladder cancer and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206769A1 (en) * 2007-01-31 2008-08-28 Applera Corporation Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof
US20090163570A1 (en) * 2006-02-09 2009-06-25 Dorla Mirejovsky Bladder cancer treatment and methods
US20090175844A1 (en) * 2005-02-10 2009-07-09 Oncotherapy Science Inc. Method of diagnosing bladder cancer
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175844A1 (en) * 2005-02-10 2009-07-09 Oncotherapy Science Inc. Method of diagnosing bladder cancer
US20090163570A1 (en) * 2006-02-09 2009-06-25 Dorla Mirejovsky Bladder cancer treatment and methods
US20080206769A1 (en) * 2007-01-31 2008-08-28 Applera Corporation Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11101038B2 (en) 2015-01-20 2021-08-24 Nantomics, Llc Systems and methods for response prediction to chemotherapy in high grade bladder cancer

Also Published As

Publication number Publication date
WO2012009382A2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2012009382A3 (en) Molecular indicators of bladder cancer prognosis and prediction of treatment response
WO2014036387A3 (en) Methods for diagnosis and treatment of cancer
WO2013096903A8 (en) Methods for prediction of clinical response to radiation therapy in cancer patients
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2010017515A3 (en) Breast cancer specific markers and methods of use
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
HK1246829A1 (en) Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
MX2010000405A (en) Drug selection for lung cancer therapy using antibody-based arrays.
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2014018563A3 (en) Methods for the treatment of cancer
BR112013004750A2 (en) quinoline and quinoxaline derivatives as kinase inhibitors
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
HK1246828A1 (en) Biomarker panel for the detection of cancer
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
EP3385717A3 (en) Methods of detecting prostate cancer
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
MX339340B (en) Methods for predicting and improving the survival of gastric cancer patients.
WO2014071067A3 (en) Treatment and diagnosis of colon cancer
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807415

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11807415

Country of ref document: EP

Kind code of ref document: A2